| MeSH term | MeSH ID | Detail |
|---|---|---|
| Breast Neoplasms | D001943 | 24 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Pancreatic Neoplasms | D010190 | 77 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Mammary Neoplasms, Experimental | D008325 | 67 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Prostatic Neoplasms | D011471 | 126 associated lipids |
| Melanoma | D008545 | 69 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Leukemia P388 | D007941 | 43 associated lipids |
| Hyperplasia | D006965 | 34 associated lipids |
| Leukemia | D007938 | 74 associated lipids |
| Leukemia, Myeloid | D007951 | 52 associated lipids |
| Bronchial Spasm | D001986 | 18 associated lipids |
| Lymphoma, B-Cell | D016393 | 24 associated lipids |
| Asthenia | D001247 | 5 associated lipids |
| Hypopharyngeal Neoplasms | D007012 | 1 associated lipids |
MAYTANSINE
MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.
Cross Reference
Introduction
To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with MAYTANSINE?
MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with MAYTANSINE
PubChem Associated disorders and diseases
What pathways are associated with MAYTANSINE
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with MAYTANSINE?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with MAYTANSINE?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with MAYTANSINE?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with MAYTANSINE?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with MAYTANSINE?
Xenograft Model
Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with MAYTANSINE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Douros J and Suffness M | New natural products of interest under development at the National Cancer Institute. | 1978 | Cancer Chemother. Pharmacol. | pmid:86390 |
| Lu D et al. | Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. | 2014 | Cancer Chemother. Pharmacol. | pmid:24939213 |
| Li C et al. | Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer. | 2016 | Cancer Chemother. Pharmacol. | pmid:27423671 |
| Wada R et al. | Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates. | 2014 | Cancer Chemother. Pharmacol. | pmid:25186956 |
| Rodon J et al. | Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. | 2008 | Cancer Chemother. Pharmacol. | pmid:18301896 |
| Girish S et al. | Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. | 2012 | Cancer Chemother. Pharmacol. | pmid:22271209 |
| Carter SK | New drugs under clinical evaluation in the United States. | 1978 | Cancer Chemother. Pharmacol. | pmid:155503 |
| Blum RH et al. | A therapeutic trial of maytansine. | 1978 | Cancer Clin Trials | pmid:757139 |
| T-DM1 aids patients with advanced breast cancer. | 2013 | Cancer Discov | pmid:24327714 | |
| T-DM1 Combo Graduates from I-SPY 2. | 2016 | Cancer Discov | pmid:27095360 | |
| Interest in "smart bombs" explodes. | 2012 | Cancer Discov | pmid:23071018 | |
| Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. | 2016 | Cancer Discov | pmid:26701087 | |
| T-DM1 Extends Survival in HER2+ Breast Cancer. | 2016 | Cancer Discov | pmid:26676162 | |
| Martin K et al. | The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. | 2014 | Cancer Immunol. Immunother. | pmid:24906866 |
| Yardley DA et al. | Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With Chemotherapy and 2 or More HER2-Targeted Agents: Results From the T-PAS Expanded Access Study. | Cancer J | pmid:26389758 | |
| Lopus M | Antibody-DM1 conjugates as cancer therapeutics. | 2011 | Cancer Lett. | pmid:21481526 |
| English DP et al. | T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. | 2014 | Cancer Med | pmid:24890382 |
| Géraud A et al. | Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. | 2016 | Cancer Radiother | pmid:27342941 |
| Rao PN et al. | Cell cycle phase-specific cytotoxicity of the antitumor agent maytansine. | 1979 | Cancer Res. | pmid:455300 |
| Perrino E et al. | Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. | 2014 | Cancer Res. | pmid:24520075 |
| RÃos-Luci C et al. | Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. | 2017 | Cancer Res. | pmid:28687619 |
| Donoso JA et al. | Maytansine action on fast axoplasmic transport and the ultrastructure of vagal axons. | 1978 | Cancer Res. | pmid:77186 |
| Ootsu K et al. | Effects of new antimitotic antibiotics, ansamitocins, on the growth of murine tumors in vivo and on the assembly of microtubules in vitro. | 1980 | Cancer Res. | pmid:6245801 |
| Ross S et al. | Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. | 2002 | Cancer Res. | pmid:11980648 |
| Tassone P et al. | In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. | 2004 | Cancer Res. | pmid:15231675 |
| Polson AG et al. | Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. | 2009 | Cancer Res. | pmid:19258515 |
| Lewis Phillips GD et al. | Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. | 2008 | Cancer Res. | pmid:19010901 |
| Kovtun YV et al. | Antibody-maytansinoid conjugates designed to bypass multidrug resistance. | 2010 | Cancer Res. | pmid:20197459 |
| Reddy JA et al. | Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate. | 2007 | Cancer Res. | pmid:17616697 |
| Henry MD et al. | A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. | 2004 | Cancer Res. | pmid:15520207 |
| Kovtun YV et al. | Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. | 2006 | Cancer Res. | pmid:16540673 |
| Erickson HK et al. | Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. | 2006 | Cancer Res. | pmid:16618769 |
| Chari RV et al. | Immunoconjugates containing novel maytansinoids: promising anticancer drugs. | 1992 | Cancer Res. | pmid:1727373 |
| Sullivan AS et al. | Interaction of rhizoxin with bovine brain tubulin. | 1990 | Cancer Res. | pmid:2364385 |
| Yalowich JC | Effects of microtubule inhibitors on etoposide accumulation and DNA damage in human K562 cells in vitro. | 1987 | Cancer Res. | pmid:2879622 |
| Tsuruo T et al. | Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. | 1986 | Cancer Res. | pmid:3753552 |
| Fellous A et al. | Effects of Tau and MAP2 on the interaction of maytansine with tubulin: inhibitory effect of maytansine on vinblastine-induced aggregation of tubulin. | 1985 | Cancer Res. | pmid:3928146 |
| Hamblett KJ et al. | SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm. | 2015 | Cancer Res. | pmid:26631267 |
| Wang L et al. | STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer. | 2018 | Cancer Sci. | pmid:30076657 |
| Wang H et al. | Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. | 2017 | Cancer Sci. | pmid:28388007 |
| Ogitani Y et al. | Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. | 2016 | Cancer Sci. | pmid:27166974 |
| Eagan RT et al. | Phase II evaluation of maytansine in patients with metastatic lung cancer. | 1978 | Cancer Treat Rep | pmid:709559 |
| Cabanillas F et al. | Phase I study of maytansine using a 3-day schedule. | 1978 | Cancer Treat Rep | pmid:348310 |
| Chabner BA et al. | Initial clinical trials of maytansine, an antitumor plant alkaloid. | 1978 | Cancer Treat Rep | pmid:348311 |
| Blum RH and Kahlert T | Maytansine: a phase I study of an ansa macrolide with antitumor activity. | 1978 | Cancer Treat Rep | pmid:348312 |
| Edmonson JH et al. | Phase II study of maytansine in advanced sarcomas. | 1983 | Cancer Treat Rep | pmid:6850657 |
| Ratanatharathorn V et al. | Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. | 1982 | Cancer Treat Rep | pmid:7093975 |
| Edmonson JH et al. | Phase II study of maytansine in advanced breast cancer. | 1981 May-Jun | Cancer Treat Rep | pmid:7237478 |
| Neidhart JA et al. | Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study. | 1980 Apr-May | Cancer Treat Rep | pmid:7427953 |
| Sabio H et al. | Maytansine in refractory childhood acute lymphocytic leukemia: a Pediatric Oncology Group study. | 1983 | Cancer Treat Rep | pmid:6580069 |